---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-24-000014"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T13:55:59.083487+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q4 2023 revenue $197M (+11% YoY); adjusted EPS $0.04; raises FY2024 revenue guidance

## Summary
- Q4 revenue $196.6M (+11% YoY); full-year 2023 revenue $753.2M (+11% YoY).
- Q4 GAAP EPS $(0.36); adjusted EPS $0.04, first positive adjusted EPS in recent quarters.
- Q4 Hereditary Cancer revenue $88.9M (+5% YoY); Prenatal $40.0M (+37% YoY); GeneSight $35.6M (+11% YoY).
- FY2024 revenue guidance raised to $820-840M (9-11% growth); adjusted EPS guidance $0.00-$0.05.
- Acquired select assets from Intermountain Precision Genomics in Feb 2024, including Precise Tumor and Liquid tests.

## SEC filing metadata
- accession: 0000899923-24-000014
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992324000014/0000899923-24-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992324000014/mygn-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-24-000014
- JSON: https://secwatch.observer/filing/0000899923-24-000014.json
- Plain text: https://secwatch.observer/filing/0000899923-24-000014.txt

## Key facts
- Earnings Releases
  MYRIAD GENETICS INC reported the three months ended December 31, 2023 results: revenue $197 million, EPS $(0.36). Guidance raised.
  - Period: the three months ended December 31, 2023
  - Revenue: $197 million
  - EPS: $(0.36)
  - Guidance: raised
  - Result: reported results
  source text: Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992324000014/0000899923-24-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.